Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Gussyup LLC dba Private Label Grooming
WARNING LETTER
•Gussyup LLC dba Private Label Grooming•February 20, 2025

Gussyup LLC dba Private Label Grooming – FDA Warning Letter, Feb 20, 2025

Record Details

The FDA issued a warning letter to Gussyup LLC, operating as Private Label Grooming, following an inspection of their Henderson, NV facility from February 18 to 20, 2025. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, as outlined in 21 CFR parts 210 and 211. Key issues included the failure of the firm"s quality control unit to ensure compliance with CGMP standards, inadequate quality systems, and the absence of a vendor qualification program. The firm also failed to conduct necessary identity tests on incoming drug components, relying instead on unverified supplier certificates of analysis, which poses risks of contamination with harmful substances like diethylene glycol or ethylene glycol.

The FDA has not received a response from Gussyup LLC regarding corrective actions for these deficiencies. The company has indicated its intention to cease production of over-the-counter drugs and has discontinued its FDA drug registration. However, the FDA requires clarification on whether the firm plans to resume drug manufacturing in the future. If so, Gussyup LLC must notify the FDA and demonstrate compliance with CGMP standards before resuming operations.

The FDA recommends that Gussyup LLC engage a qualified CGMP consultant to conduct a comprehensive audit and assist in addressing the violations. The firm must respond in writing within 15 working days, detailing corrective actions taken and plans to prevent recurrence. Failure to adequately address these issues may result in regulatory actions, including seizure, injunction, or withholding of approvals and contracts.

Company
Gussyup LLC dba Private Label Grooming
Inspection date
February 20, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · f962d30d-24e8-4256-99a5-ea6a1188b12d

Violation Codes7
21 CFR 21021 CFR 21121 U.S.C. 351(a)(2)(B)21 CFR 211.2221 CFR 211.84(d)(1)21 CFR 211.84(d)(2)21 CFR 211.34

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Gussyup LLC dba Private Label Grooming
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.